UCSF-led study points to pivotal, early event in cancer development

Researchers led by UCSF scientists report that they may have identified a pivotal - and very early -- event in the development of breast cancer, with an unexpected revelation regarding the behavior of mammary epithelial cells. The finding, they say, could point to a new target for very early detection and treatment of breast cancer.

The investigation was conducted in cell culture studies of mammary epithelial cells, in which breast cancer develops. However, because greater than 90 percent of cancers originate in epithelial cells, the finding could have broader implications for understanding carcinogenesis, says the senior author of the study, Thea Tlsty, PhD, UCSF professor of pathology.

The discovery was an outcome of studies supported by the UCSF Breast SPORE (Specialized Program in Organ Research Excellence), a funding mechanism established by the National Cancer Institute aimed at supporting basic scientists in work on translational research.

In their study, the researchers discovered that mammary epithelial cells are unexpectedly prone to spontaneously surmounting a built-in regulatory control on cell growth known as senescence, and that when they do escape this check, they almost always develop the multiple, simultaneous genetic changes associated with the earliest stages of cancer development.

"Until now, we've thought senescence could be relied upon as a barrier to continued cell growth," says Tlsty. "Our cell culture study of mammary epithelial cells suggests otherwise.

"We hypothesize that the mammary epithelial cells escape from senescence and acquire genomic instability to produce the types of genetic changes that occur at the very beginning of breast cancer. Our next step is to determine if these changes take place in animal models. Nobody has understood why the majority of cancer cells are epithelial in origin. This finding offers a possible explanation."

The researchers identified molecular markers that ind

Contact: Jennifer O'Brien
University of California - San Francisco

Page: 1 2 3 4

Related biology news :

1. UCSF-led study raises doubts about marrow cell treatment for brain, heart
2. UCSF-led team reports new test improves detection of prions in animals
3. UCSF-led study offers insight into cancer development, resistance to therapy: finding focuses on Ras oncogene
4. Student science contest participation influences study, career choices, alumni say
5. New study shows hope for treating inhalant abuse
6. International study findings link acne-like rash to effectiveness of new targeted cancer treatment
7. Cigarette smoke causes breaks in DNA and defects to a cells chromosomes, Pitt study finds
8. New study indicates arsenic could be suitable as first-line treatment in type of leukaemia
9. Phase II trials of second-generation antisense cancer drug planned following successful early study
10. Preclinical safety study shows adipose-derived stem cells improve heart function after heart attack
11. Indiana University, EPA to study airborne PCBs

Post Your Comments:

(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
Breaking Biology Technology:
Cached News: